Samuel R. Denmeade
Johns Hopkins University
266 Papers
2.1K Citations
Samuel R. Denmeade is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 57, co-authored 229 publications. Previous affiliations of Samuel R. Denmeade include Johns Hopkins University School of Medicine.
Chat about Author
Papers
Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells.
TL;DR: This study was undertaken to determine if caspase inhibition can prevent TG‐ or 5‐fluorodeoxyuridine (5‐FrdU)‐induced apoptosis in prostate cancer cells.
28
Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
TL;DR: Emetine is converted to a prodrug activatable by the fibroblast activation protein (FAP), a serine protease overexpressed by the carcinoma associated fibroblasts, which can be selectively delivered to cancer cells in the region of metastatic cancer as a pro drug that will be activated by an enzyme selectively overexpression within the metastatic tumor microenvironment.
Anti‐tumor effect of combination therapy with intratumoral controlled‐release paclitaxel (PACLIMER® microspheres) and radiation
Rena G. Lapidus,Wenbin Dang,David Marc Rosen,Alyssa M. Gady,Yelena Zabelinka,Robert N. O'Meally,Theodore L. DeWeese,Samuel R. Denmeade +7 more
TL;DR: Local delivery of a controlled‐release pac litaxel product may allow for increase local concentrations of paclitaxel at the tumor site and, in conjunction with radiation, may enhance cell kill by its radiosensitization mechanism.
28
Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate Cancer.
Matthew P. Deek,Kekoa Taparra,Dyda Dao,Luanna Chan,Ryan Phillips,R.W. Gao,Eugene D. Kwon,Curtiland Deville,Danny Y. Song,Stephen Greco,Michael A. Carducci,Mario A. Eisenberger,Theodore L. DeWeese,Samuel R. Denmeade,Kenneth J. Pienta,Channing J. Paller,Emmanuel S. Antonarakis,Kenneth R. Olivier,Sean S. Park,Bradley J. Stish,Phuoc T. Tran,Phuoc T. Tran +21 more
TL;DR: After MDT, the majority of patients have long-term control or oligoprogression (class I or II).
28
The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications
TL;DR: The bipolar androgen therapy (BAT) as discussed by the authors is a commonly used treatment for prostate cancer, which involves rapid cycling from supraphysiological back to near-castration testosterone levels over a 4-week cycle.
28